Regeneus Ltd (ASX:RGS) Presentation for AusBiotech 2018
Sydney, Oct 31, 2018 - (ABN Newswire) - Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, is pleased to announce John Martin, CEO, will present at the AusBiotech 2018 Conference today.
The annual AusBiotech conference brings together Australian and international biotech leaders and stakeholders. For more than three decades, the event has created a forum to reflect on the sector's achievements and exchange ideas to further advance the sector's standing both nationally and globally. AusBiotech is dedicated to consolidating this growth.
John Martin was invited to present as part of the Regenerative Medicine Stream. His session will focus on the successful translation and commercialisation of novel regenerative medicines by Australian companies. MTPConnect, the Australian Government's medtech and pharma growth centre, launched a report entitled 'Regenerative Medicine: Opportunities for Australia' at the beginning of the session. The report was produced in collaboration with AusBiotech's Regenerative Medicine Advisory Group, of which John Martin is a member, as well as other key stakeholders from industry and the research sector.
The following are specific details regarding Regeneus' presentation:
Event: AusBiotech 2018
Date: 31 October 2018
Time: 2.30pm (AEST)
Location: Room 2, Brisbane Convention and Exhibition Centre, Southbank, Brisbane
To view the presentation, please visit:
http://abnnewswire.net/lnk/
WEB: Presentation for AusBiotech 2018
About: Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.
Contact:
Sandra McIntosh
Company Secretary and Investor Relations
Regeneus Ltd
T: +61-2-9499-8010
E: investors@regeneus.com.au
Media
Imogen Conyers
Media and Capital Partners
T: +61-405-191-257
E: imogen.conyers@mcpartners.com.au
Oct 31, 2018
Source: Regeneus Ltd(ASX:RGS)
Copyright (C) 2018 ABN Newswire. A division of ABN IR